Bob G Gower bought $182k of ENSC
director at Ensysce Biosciences, Inc.. 379,300 shares at an average of $0.48, traded Feb 28, 2023, filed Mar 2, 2023.
Score components
- +15RoleDirector
- +12Trade size$182k at market
- +10Relative to holdingsHoldings up 50%
- +18Price context2% above the 52-week low; 98% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-23-006553, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 28, 2023 | POpen-market purchase Common Stock | +109,300 | $0.49 | $53k | 862,395 | Mar 2, 2023 |
| Mar 1, 2023 | POpen-market purchase Common Stock | +270,000 | $0.48 | $129k | 1,132,395 | Mar 2, 2023 |
Related signals
Other insiders at Ensysce Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 42Moderate | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $444k 908,614 shares | first purchase | |
| 37Weak | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $44k 90,287 shares | +8% | |
| 51Moderate | ENSCbuy Ensysce Biosciences, Inc. | Bob G Gower director | $500k 357,143 shares | +90% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.